C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

Posted by Peter Garcia-Meza on May 07, 2014

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced excellent interim results for its Coldplay Cryoballoon Focal Ablation System at the Digestive Disease Week (DDW) in Chicago. Data from the study titled, “Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett's esophagus” were presented in a poster session today by Bas Weusten, MD, Professor of Innovative Gastrointestinal Endoscopy Senior Gastroenterologist, St. Antonius Hospital Nieuwegein, The Netherlands, and trial’s Principal Investigator.

Click here for full release.

Two Clinical Studies to be Presented at DDW 2014

Posted by Peter Garcia-Meza on May 02, 2014

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced that data from two clinical studies evaluating the therapeutic impact of its Coldplay Cryoballoon Focal Ablation System will be presented at Digestive Disease Week® (DDW®), on May 6th in Chicago, IL.

C2 Therapeutics DDW 2014 Clinical Study Announcement Card.

Click here for full press release.

C2 Therapeutics Receives FDA Clearance

Posted by Peter Garcia-Meza on Aug 22, 2013

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett's Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company's second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation ...

Click here to see full release.

West Penn Allegheny Clinical Trial Tests New Barrett's Esophagus Treatment

Posted by Peter Garcia-Meza on Jun 11, 2013

West Penn Allegheny Health System researchers are investigating whether a new ablation technology can provide safer and more effective treatment for patients with Barrett's Esophagus, a condition associated with gastroesophageal reflux disease (GERD) that can progress to esophageal cancer if left untreated.

Click here for the full story.

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

Posted by Peter Garcia-Meza on May 02, 2013

C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

Click here for full release.

C2 Therapeutics

303 Convention Way
Suite 1
Redwood City, CA 94063
(650) 521-5304